Suppression of apolipoprotein B secretion from HepG2 cells by glucosyl hesperidin

Journal of Nutritional Science and Vitaminology

Volumn 52, Issue 3, 2006, Pages 223-231

  Miwa, Yoshikatsu ^a   Mitsuzumi, Hitoshi ^a   Yamada, Mika ^a   Arai, Norie ^a   Tanabe, Fujimi ^a   Okada, Katsuhide ^a   Kubota, Michio ^a   Chaen, Hiroto ^a   Sunayama, Takahiro ^b   Kibata, Masayoshi ^a,c  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^b Hayashibara Co Ltd ^*  (Japan)

^c Department of Internal Medicine   (Japan)

Author keywords

Apolipoprotein B; Cholesteryl ester; Glucosyl hesperidin; HepG2 cells; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER; HESPERIDIN; OLEIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CELL STIMULATION; CELL STRAIN HEPG2; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME;

ANALYSIS OF VARIANCE; APOLIPOPROTEINS B; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CHOLESTEROL ESTERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSIDES; HESPERIDIN; HUMANS; LIPOPROTEINS, VLDL; LIVER NEOPLASMS; MODELS, BIOLOGICAL; TIME FACTORS; TRIGLYCERIDES;

EID: 33746888685     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.52.223     Document Type: Article

References (47)

1. Garg A, Garg S, Zaneveld LJD, Singla AK. 2001. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 15: 655-669.
2. Galati EM, Trovato A, Kirjavainen S, Forestieri AM, Rossitto A, Monforte MT. 1996. Biological effects of hesperidin, a citrus flavonoid (Note III): Antihypertensive and diuretic activity in rat. IL Farmaco 51: 219-221.
3. Galati EM, Monforte MT, Kirjavainen S, Forestieri AM, Trovato A, Tripodo MM. 1994. Biological effects of hesperidin, a citrus flavonoid (Note I): Antiinflammatory and analgesic activity. IL Farmaco 49: 709-712.
4. Hijiya H, Miyake T. 1991. Alpha-glycosyl hesperidin, and its preparation and uses. European Patent Publication No. 0402049.
5. Kometani T, Terada Y, Nishimura T, Takii H, Okada S. 1994. Transglycosylation to hesperidin by cyclodextrin glucanotransferase from an alkalophilic Bacillus species in alkaline pH and properties of hesperidin glycosides. Biosci Biotechnol Biochem 58: 1990-1994.
6. Yamada M, Mitsuzumi H, Tsuzaki Y, Miwa Y, Chaen H, Yamamoto I. 2003. Antioxidant activity of glycosylated vitamin P and its suppressive effect on oxidative stress in hyperlipidemic mice. J Jpn Soc Nutr Food Sci 56: 355-363.
7. Ohtsuki K, Abe A, Mitsuzumi H, Kondo M, Uemura K, Iwasaki Y, Kondo Y. 2002. Effects of long-term administration of hesperidin and glucosyl hesperidin to spontaneously hypertensive rats. J Nutr Sci Vitaminol 48: 420-422.
8. Ohtsuki K, Abe A, Mitsuzumi H, Kondo M, Uemura K, Iwasaki Y, Kondo Y. 2003. Glucosyl hesperidin improves serum cholesterol composition and inhibits hypertrophy in vasculature. J Nutr Sci Vitaminol 49: 447-450.
9. Nishizaki Y, Tatefuji T, Akamatsu S, Hanaya T, Arai S, Ikeda M, Kurimoto M. 1997. Anti-allergic effect of α-glucosyl-hesperidin. Med Biol 135: 199-204.
10. Miwa Y, Yamada M, Sunayama T, Mitsuzumi H, Tsuzaki Y, Chaen H, Mishima Y, Kibata M. 2004. Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level. J Nutr Sci Vitaminol 50: 211-218.
11. Miwa Y, Mitsuzumi H, Sunayama T, Yamada M, Okada K, Kubota M, Chaen H, Mishima Y, Kibata M. 2005. Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality. J Nutr Sci Vitaminol 51: 460-470.
12. Takata K. 2001. The metabolic regulation of TG-rich lipoproteins. Nippon Rinsho 59 (Suppl 2): 472-476.
13. Daubresse JC, Machowski R, Pulinx E. 1994. Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia. Acta Clin Belg 49: 68-75.
14. Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, Yamada N. 2002. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 71: 2403-2412.
15. Olofsson SO, Asp L, Boren J. 1999. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol 10: 341-346.
16. Boren J, Rustaeus S, Olofsson SO. 1994. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J Biol Chem 269: 25879-25888.
17. Wilcox LJ, Barrett PHR, Newton RS, Huff MW. 1999. ApoB 100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of apoB. Arterioscler Thromb Vasc Biol 19: 939-949.
18. Haghpassand M, Wilder D, Moberly JB. 1996. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J Lipid Res 37: 1468-1480.
19. Ellsworth JL, Erickson SK, Cooper AD. 1986. Very low and low density lipoprotein synthesis and secretion by the human hepatoma cell line Hep-G2: effects of free fatty acid. J Lipid Res 27: 858-874.
20. Thrift RN, Forte TM, Cahoon BE, Shore VG. 1986. Characterization of lipoproteins produced by the human liver cell line, HepG2, under defined conditions. J Lipid Res 27: 236-250.
21. Gibbons GF. 1994. A comparison of in-vitro models to study hepatic lipid and lipoprotein metabolism. Curr Opin Lipidol 5: 191-199.
22. Zhu D, Ganji SH, Kamanna VS, Kashyap ML. 2002. Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis 164: 221-228.
23. Arrol S, Mackness MI, Durrington PN. 2000. The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). Atherosclerosis 150: 255-264.
24. Dixon JL, Furukawa S, Ginsberg HN. 1991. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 266: 5080-5086.
25. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
26. Carr TP, Andresen CJ, Rudel LL. 1993. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 26: 39-42.
27. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
28. Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. 1996. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 60: 34-40.
29. Matsumoto H, Ikoma Y, Sugiura M, Yano M, Hasegawa Y. 2004. Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J Agric Food Chem 52: 6653-6659.
30. Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Rémésy C. 2003. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr 57: 235-242.
31. Cianflone KM, Yasruel Z, Rodriguez MA, Vas D, Sniderman AD. 1990. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res 31: 2045-2055.
32. Wu X, Sakata N, Lui E, Ginsberg HN. 1994. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. J Biol Chem 269: 12375-12382.
33. Wilcox LJ, Barrett PHR, Huff MW. 1999. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res 40: 1078-1089.
34. Macri J, Adeli K. 1997. Conformational changes in apolipoprotein B modulate intracellular assembly and degradation of apoB-containing lipoprotein particles in HepG2 cells. Arterioscler Thromb Vasc Biol 17: 2982-2994.
35. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. 1998. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 18: 783-793.
36. Chiba H, Uehara M, Wu J, Wang X, Masuyama R, Suzuki K, Kanazawa K, Ishimi Y. 2003. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr 133: 1892-1897.
37. Wisselaar HA, van Dongen JM, Reuser AJ. 1989. Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells. Clin Chim Acta 182: 41-52.
38. Gebhardt R. 2002. Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase pretreatment. Phytother Res 16: 368-372.
39. Shimakata T. 2001. Triacylglycerol, diacylglycerol, monoacylglycerol. Nippon Rinsho 59 (Suppl 2): 21-28.
40. Chang TY, Chang CC, Cheng D. 1997. Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem 66: 613-638.
41. Seo T, Oelkers PM, Giattina MR, Worgall TS, Sturley SL, Deckelbaum RJ. 2001. Differential modulation of ACAT1 and ACAT2 transcription and activity by long chain free fatty acids in cultured cells. Biochemistry 40: 4756-4762.
42. Musanti R, Giorgini L, Lovisolo PP, Pirillo A, Chiari A, Ghiselli G. 1996. Inhibition of acyl-CoA:cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J Lipid Res 37: 1-14.
43. Bok SH, Lee SH, Park YB, Bae KH, Son KH, Jeong TS, Choi MS. 1999. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl- CoA reductase and acyl CoA:cholesteroI transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J Nutr 129: 1182-1185.
44. Borradaile NM, Carroll KK, Kurowska EM. 1999. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids 34: 591-598.
45. Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. 2001. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res 42: 725-734.
46. Murase T, Nagasawa A, Suzuki J, Hase T, Tokimitsu I. 2002. Beneficial effects of tea catechines on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 26: 1459-1464.
47. Hisatomi A, Yamamoto K. 2001. Apolipoprotein B (apoB100, apoB48). Nippon Rinsho 59 (Suppl 2): 109-113.